Abstract:A series of 10-amino-6,8,12,12a-tetrahydro-5H-thiazolo[4',5':4,5]pyrido[2,1-a] isoquinolines with substituent hydroxyl or methoxyl groups at C2 and C3 positions of the benzene ring were designed and synthesized. These compounds are 2-aminothiazole bioisosteres of the natural product stepholidine (SPD). Radioligand binding assays showed that compounds 10a, 10b, 10c and 12b had moderate binding affinity and activity for the D1 receptor, as well as high selectivity over the D2 receptor. Among them, 10c exhibited moderate D3 receptor binding affinity. 10a with an amino group in position 10 showed higher affinities toward D3 receptor compared to those without an amino group. In silico docking analysis of active ligands was performed to explain the result of binding assays and analyze structure-activity relationship for further structure optimization. Our analysis suggested that besides the salt bridge interaction formed by the conserved D3.32 with the protonated nitrogen of ligands and the hydrogen bonds formed by S5.42 with 2-hydroxyl group and S5.46 with 3-methoxyl group, a hydrogen bond formed between S188 located on the second extracellular loop (ECL2) and the nitrogen in the thiazole ring was critical to the affinity of this series of compounds for the D1 receptor, which was in agreement with the interaction mode between SPD and the D1 receptor. Â Our results suggested that the introduction of thiazole ring changes the pharmacological profile of SPD and the optimized compounds have high selective activity to D1 receptor over D2 receptor. These thiazole-SPD-derivative compounds have potential clinical use in Parkinsonâ€™s disease and other conditions related to dopamine receptors.

Discovery of N-cyclobutylaminoethoxyisoxazole Derivatives As Novel Sigma-1 Receptor Ligands with Neurite Outgrowth Efficacy in Cells

Synthesis and Neuroprotective Biological Evaluation of Quinazolinone Derivatives Via Scaffold Hopping.

Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases

Synthesis and Biological Evaluation of Novel Σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones

From Α4β2 Nicotinic Ligands to the Discovery of Σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.

Synthesis and Biological Evaluation of Novel 6,7-Dihydro-5h-cyclopenta[d]pyrimidine and 5,6,7,8-Tetrahydroquinazoline Derivatives As Sigma-1 (σ1) Receptor Antagonists for the Treatment of Pain.

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.

Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy

Synthesis and Biological Evaluation of σ1 Receptor Ligands Based on Phenyl-1,2,4-oxadiazole Derivatives.

Design and Synthesis of New Acyl Urea Analogs as Potential σ1R Ligands

Discovery of 3‐(2‐aminoethyl)‐thiazolidine‐2,4‐diones as a Novel Chemotype of Sigma‐1 Receptor Ligands

Studies on the affinity of 6-[(n-(cyclo)aminoalkyl)oxy]-4 H-chromen-4-ones for sigma 1/2 receptors

Discovery of Novel Pyrimidine-Based Derivatives as Nav1.2 Inhibitors with Efficacy in Mouse Models of Epilepsy

Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.

Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability

Discovery and development of brain-penetrant 18F-labeled radioligands for neuroimaging of the sigma-2 receptors

From dopamine 4 to sigma 1: Synthesis, SAR and biological characterization of a piperidine scaffold of σ1 modulators

Synthesis, Preliminary Pharmacological Evaluation and Receptor Docking Studies of 10-Amino-3-methoxy-6,8,12,12a-tetrahydro-5h-thiazolo[4',5':4,5]Pyrido[2,1-a]isoquinolin-2-ols As Novel Dopamine D1 Receptor Inhibitors

Isoquinolinone derivatives as potent CNS multi-receptor D2/5-HT1A/5-HT2A/5-HT6/5-HT7 agents: Synthesis and pharmacological evaluation

Isoquinolinone Derivatives As Potent CNS Multi-Receptor D2/5-HT1A/5HT2A/5-HT6/5-HT7 Agents: Synthesis and Pharmacological Evaluation